RP2 retains the design features of RP1, with the added expression of an anti-CTLA-4 antibody-like molecule designed to be expressed within tumors and secreted into the local tumor microenvironment for local CTLA-4 blockade on T cells within tumors [55]. This evidence concerns the gene CTLA4 and neoplasm.